HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health, Beauty And Wellness News: Vitamin Shoppe Trims Loss, GNC Closes Hayao Pact, AlchemLife In US

This article was originally published in The Rose Sheet

Executive Summary

Puriton Eye Relief Drops recalled; Alchem International adds US to distribution; Vitamin Shoppe CEO: 'expeditiously turn business around'; GNC closes Hayao investment deal.

You may also be interested in...



Competing Bidder For GNC Argues Expected Sale To Chinese Firm Would Cause Security Risks In US

DynamicVetnures also contends Harbin Pharmaceutical is attempting to avoid a regulatory review by federal agencies on national security and other questions that is required when foreign companies make large investments in US businesses.

GNC’s Bankruptcy Targets Sale To Harbin Pharma, With Reorganization Also An Option

Chapter 11 bankruptcy protection filing positions largest shareholder Harbin Pharmaceutical to acquire full ownership for $760m. But petition also gives it an option of reorganizing with $525m financing if a sale is not completed within 141 days.

GNC Missed Opportunities To Drive Growth On Changing Trends

Jefferies analysts point out more sales of supplements, particularly sports nutrition products, already were moving online before COVID-19 prompted quarantine orders and spike e-commerce sales. GNC could have capitalized but didn’t have capital available to make its online sales platform and operations large enough to support potential growth.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS122417

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel